Last Updated:December 18, 2025, 19:58 IST The UK trial shows children receiving the combination saw their tumours shrink & had longer periods of progression-free survival, meaning cancer stayed under control for more time Paediatric oncologists point out that many Indian families struggle to complete even conventional treatment sequences due to travel, accommodation, and financial burdens. (Getty Images) A new clinical trial from the UK, published on December 12 in the Journal of Clinical Oncology, has reported something rare in paediatric cancer research: a treatment combination that significantly improves survival in children diagnosed with neuroblastoma, one of the most aggressive childhood cancers. The study shows that adding an antibody therapy called dinutuximab beta to standard chemotherapy does more than shrink tumours. It extends the time before the cancer grows again and improves overall survival. In India, where childhood cancers are often diagnosed late, treatment is limited, and survival rates vary between major cities and smaller towns, the new finding has immediate implications. The question now is whether this new therapy, already approved in parts of Europe, …